Comparative Pharmacology
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN AND POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENOSYL versus NEOMYCIN AND POLYMYXIN B SULFATE.
GENOSYL vs NEOMYCIN AND POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. Polymyxin B sulfate is a cationic detergent that disrupts bacterial cell membrane permeability by interacting with phospholipids, leading to cell death.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
For irrigation of urinary bladder: 1 mL of solution containing 40 mg neomycin and 200,000 units polymyxin B per mL diluted in 1 liter of 0.9% sodium chloride, instilled via continuous irrigation at a rate of 1 liter per 24 hours. For topical use: apply thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Neomycin: 2-3 hours (normal renal function), prolonged to 24-48 hours in renal impairment; Polymyxin B: 4.5-6 hours (normal renal function), extended significantly in renal failure.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Renal: ~90-95% (neomycin, polymyxin B) unchanged; fecal: 5-10% (biliary excretion negligible).
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic